首页> 美国卫生研究院文献>International Journal of Nanomedicine >The prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2−) subtype breast cancer by quantum-dot-based molecular imaging
【2h】

The prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2−) subtype breast cancer by quantum-dot-based molecular imaging

机译:基于量子点的分子成像定量分析管腔B(HER2-)亚型乳腺癌中CCL5和胶原蛋白IV的预后价值

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ObjectiveBreast cancer is the most common malignancy and one of the main causes of death in women. Luminal B (HER2−) breast cancer subtype has been proposed since the 2011 St Gallon consensus. The hormone receptor status in this type of breast cancer is positive; thus, endocrine therapy was performed in all cases, but the treatment was not satisfactory, and a significant number of cases received very little benefit from chemotherapy. Furthermore, there is no effective treatment target for this subtype. Luminal B (HER2−) breast cancer subtype has been proposed since the 2011 St Gallon consensus. Therefore, the study of the key molecules in the microenvironment of breast cancer can help to reveal the biological characteristics.
机译:目的乳腺癌是最常见的恶性肿瘤,是女性死亡的主要原因之一。自2011年圣加仑共识以来,已经提出了Luminal B(HER2-)乳腺癌亚型。这类乳腺癌的激素受体状态为阳性;因此,所有病例均进行了内分泌治疗,但治疗效果不理想,并且很多病例很少从化疗中受益。此外,没有针对该亚型的有效治疗靶标。自2011年圣加仑共识以来,已经提出了Luminal B(HER2-)乳腺癌亚型。因此,对乳腺癌微环境中关键分子的研究有助于揭示其生物学特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号